Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Dose Escalation Study Assessing the Safety and Treatment Effects of MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema

NCT04187443 is registered in ClinicalTrials.gov with Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT04187443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04187443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Dose Escalation Study Assessing the Safety and Treatment Effects of MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
Lead sponsor
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
June 2, 2020
Completion date
December 30, 2026
Enrollment
45 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema, diabetic retinopathy, macular edema, type 1 diabetes with diabetic macular edema, type 2 diabetes with diabetic macular edema